Literature DB >> 29491754

Gabapentin Improves Oral Feeding in Neurologically Intact Infants With Abdominal Disorders.

Keliana L O'Mara, Saleem Islam, Janice A Taylor, Daniel Solomon, Michael D Weiss.   

Abstract

Feeding intolerance, poor oral feeding skills, and retching are common symptoms seen in medically complex infants with a history of abdominal disorders and surgical interventions, such as gastrostomy tube placement and Nissen fundoplication. Visceral hyperalgesia may play a role in the underlying pathophysiology. We report the use of orally administered gabapentin in 3 infants with presumed visceral hyperalgesia presenting as poor tolerance of enteral and oral feeds. Retching and outward discomfort associated with feeds was resolved within 2 to 3 days of initiation of therapy. Full oral feeds were obtained in all 3 patients within 3 to 4 months of starting gabapentin without changing adjunctive medications or therapies. After attainment of full oral feeds, all patients were successfully weaned off gabapentin over a month, with no notable side effects, signs of withdrawal, or impact on ability to feed by mouth.

Entities:  

Keywords:  gabapentin; infant; neonate; oral feeding; visceral hyperalgesia

Year:  2018        PMID: 29491754      PMCID: PMC5823495          DOI: 10.5863/1551-6776-23.1.59

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  15 in total

1.  Gabapentin successfully manages chronic unexplained irritability in children with severe neurologic impairment.

Authors:  Julie M Hauer; Beverly S Wical; Lawrence Charnas
Journal:  Pediatrics       Date:  2007-02       Impact factor: 7.124

2.  Self-assessed physical health among children with congenital diaphragmatic hernia.

Authors:  Elin Öst; Maria Öjmyr Joelsson; Carmen Mesas Burgos; Björn Frenckner
Journal:  Pediatr Surg Int       Date:  2016-02-24       Impact factor: 1.827

3.  Treatment with gabapentin associated with resolution of apnea in two infants with neurologic impairment.

Authors:  Julie Hauer; Daniel Mackey
Journal:  J Palliat Med       Date:  2012-08-07       Impact factor: 2.947

4.  Neonatal stress from limited bedding elicits visceral hyperalgesia in adult rats.

Authors:  Yumei Guo; Zhuo Wang; Emeran A Mayer; Daniel P Holschneider
Journal:  Neuroreport       Date:  2015-01-07       Impact factor: 1.837

5.  Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome.

Authors:  K J Lee; J H Kim; S W Cho
Journal:  Aliment Pharmacol Ther       Date:  2005-11-15       Impact factor: 8.171

6.  Gastrointestinal motility and sensory abnormalities may contribute to food refusal in medically fragile toddlers.

Authors:  Tsili Zangen; Carla Ciarla; Samuel Zangen; Carlo Di Lorenzo; Alex F Flores; Jose Cocjin; Sarabudla Narasimha Reddy; Anita Rowhani; Lenore Schwankovsky; Paul E Hyman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2003-09       Impact factor: 2.839

7.  The long term physical consequences of gastroschisis.

Authors:  Emma L Harris; Corrado Minutillo; Susannah Hart; Teresa M Warner; Madhur Ravikumara; Elizabeth A Nathan; Jan E Dickinson
Journal:  J Pediatr Surg       Date:  2014-10       Impact factor: 2.545

8.  Alpha 2 Delta (α(2)δ) Ligands, Gabapentin and Pregabalin: What is the Evidence for Potential Use of These Ligands in Irritable Bowel Syndrome.

Authors:  Jeremy D Gale; Lesley A Houghton
Journal:  Front Pharmacol       Date:  2011-06-09       Impact factor: 5.810

9.  Early life stress elicits visceral hyperalgesia and functional reorganization of pain circuits in adult rats.

Authors:  D P Holschneider; Y Guo; E A Mayer; Z Wang
Journal:  Neurobiol Stress       Date:  2016-06-01

10.  Retrospective Study of Gabapentin for Poor Oral Feeding in Infants With Congenital Heart Disease.

Authors:  Amanda Schurle Bruce; Ann McGrath Davis; Carrie Firestone Baum; Debbie Chepolis; Andrew Kolomensky; Javier Monagas; Osama Almadhoun; Paul Hyman
Journal:  Glob Pediatr Health       Date:  2015-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.